Skip to content
MARKETS / BALCAO / BIXT
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Bioxytran, Inc. BIXT

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$-2.1M
In brief

What this company does

Bioxytran, Inc. is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design. We were incorporated on June 9, 2008, as America’s Driving Ranges, Inc.. On September 21, 2018, the Company was reorganized into Bioxytran through a reverse merger to focus on the development, manufacturing and commercialization of therapeutic drugs designed to address Hypoxia and Degenerative Diseases and antiviral treatment in humans. Pharmalectin, Inc. (the “Pharmalectin”) is a subsidiary focused on the development, manufacture and commercialization of therapeutic drugs designed to address conditions related to viral diseases. Bioxytran uses Galectin inhibitors to combat the virus, SARS-CoV-2. Bioxytran is also developing treatments for hypoxic conditions, necrosis, and degenerative diseases that utilize the carrying of oxygen to affected areas for stroke, wound, and brain damage treatment.

Written from the business description in Bioxytran, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 15 April 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2017 · Revenue 0.2 · Net income -0.3
-2M-4M200920112013201520172019202120232025
Compound annual growth
−11.5%
−9.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −9.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2017 · Operating -162.5% · Net -166.6%
-2000%-4000%200920112013201520172019202120232025
ROE
FY2013 · ROE -828.2%
-5000%200920112013201520172019202120232025

Cash & shareholders
returned in FY2025 · dividends + net buybacks

Total assetsUSD 658,552.00
Gross debtUSD 50,000.00
DepositsUSD 111,547.00
Current ratio0.16×

Not available: we don't have the cash figure for this period.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B········0.00.00.00.00.00.00.00.0·
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·
EBITDA $B········−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·
Income tax $B·······0.0·········
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.02−0.02−0.03−0.02−0.04−0.03−0.020.00−0.01−0.03−0.21−0.30−0.47−0.02−0.06−0.01·
Dividend / sh $·················
Payout %·················
ROE %············−828.2−886.6−8264.8··
Shares out B0.110.090.140.120.110.100.090.090.090.030.010.010.000.160.110.03·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 71 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 24 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image